Top

BMC Urology

Published in:

Open Access 01-12-2006 | Research article

Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder

Authors: Andrea Staack, Steffen Badendieck, Dietmar Schnorr, Stefan A Loening, Klaus Jung

Published in: BMC Urology | Issue 1/2006

Abstract

Background

Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play a major role in the maintenance of extracellular matrix homeostasis and are involved in the process of tumour invasion and metastasis in several malignant tumour entities. The goal of this study is to evaluate the diagnostic value of various circulating MMPs and TIMPs in blood plasma for a non-invasive detection of transitional cell carcinoma of the bladder (TCC).

Methods

In this study the concentrations of MMP1, MMP2, MMP3, MMP9, their inhibitors TIMP1, TIMP2, and the MMP1/TIMP1-complex (MTC1) were quantified in blood plasma with the sandwich enzyme-linked immunosorbent assay (ELISA). Blood plasma samples were investigated from 68 patients (non-metastasized, n = 57 and metastasized, n = 11) with TCC of the bladder and from 79 healthy controls. The mROC program was used to calculate the best two- and three- marker combinations. The diagnostic values for all single markers and the marker combinations were estimated both by the overall diagnostic performance index area under the ROC curve (AUC) and the sensitivity and specificity at cutoff limits with the highest diagnostic accuracy and at the 90% and 95% limits of sensitivity and specificity, respectively.

Results

The median MMP2 concentration was elevated in blood plasma in all patient groups with TCC in comparison to the controls (p < 0.001). The concentrations of TIMP1, TIMP2, and MTC1 in plasma probes were significantly lower from patients with non-metastasized TCC compared to the controls. MMP2 tested alone reached the highest sensitivity and specificity at 75%, respectively. The sensitivity and specificity increased when tested in combination with MMP9 and TIMP1 (97%, 94%, respectively). The combination of MMP9 and TIMP1 also showed an improved sensitivity (80%) and specificity (99%) than tested alone.

Conclusion

MMP2 is a statistically significant marker in blood plasma for bladder cancer detection with an increased diagnostic value in combination with MMP9 and TIMP1. This study showed that the highest sensitivities and specificities are not obtained by testing each marker alone. As shown by the best two-marker combination, which includes MMP9 and TIMP1, the optimized combination does not always include the best single markers.

Available only for authorised users

Society AC: Cancer Facts and Figures 2006. http://wwwcancerorg/docroot/STT/stt_0asp. Edited by: American Cancer Society I. 2006

Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I: Current concepts in biomarker technology for bladder cancers. Clin Chem. 2000, 46: 595-605.PubMed

Koenig F, Jung K, Schnorr D, Loening SA: Urinary markers of malignancy. Clin Chim Acta. 2000, 297: 191-205. 10.1016/S0009-8981(00)00246-1.CrossRefPubMed

Vasala K, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 2003, 62: 952-957. 10.1016/S0090-4295(03)00660-5.CrossRefPubMed

Gontero P, Banisadr S, Frea B, Brausi M: Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol. 2004, 46: 296-311. 10.1016/j.eururo.2004.04.001.CrossRefPubMed

Staack A, Koenig F, Daniltchenko D, Hauptmann S, Loening SA, Schnorr D, Jung K: Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. Urology. 2002, 59: 308-312. 10.1016/S0090-4295(01)01517-5.CrossRefPubMed

Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001, 57: 675-679. 10.1016/S0090-4295(00)01087-6.CrossRefPubMed

Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF, Kinders RJ, Raitanen M, Meri S, Jokiranta TS: Complement factor H as a marker for detection of bladder cancer. Clin Chem. 2005, 51: 856-863. 10.1373/clinchem.2004.042192.CrossRefPubMed

Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA: Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res. 2005, 25: 635-641.PubMed

10.

Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed

11.

Chen WT: Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol. 1992, 4: 802-809. 10.1016/0955-0674(92)90103-J.CrossRefPubMed

12.

Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991, 64: 327-336. 10.1016/0092-8674(91)90642-C.CrossRefPubMed

13.

Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 2004, 49: 179-186.CrossRefPubMed

14.

Mott JD, Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004, 16: 558-564. 10.1016/j.ceb.2004.07.010.CrossRefPubMedPubMedCentral

15.

Nakopoulou L, Gakiopoulou H, Zervas A, Giannopoulou I, Constantinides C, Lazaris AC, Liapis H, Kyriakou G, Dimopoulos C: MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol. 2001, 9: 130-137. 10.1097/00022744-200106000-00005.PubMed

16.

Guan KP, Ye HY, Yan Z, Wang Y, Hou SK: Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003, 61: 719-723. 10.1016/S0090-4295(02)02429-9.CrossRefPubMed

17.

Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004, 49: 187-198.CrossRefPubMed

18.

DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE: Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 1991, 51: 2151-2157.PubMed

19.

Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989, 264: 17374-17378.PubMed

20.

Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M: Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer. 1998, 77: 650-655.CrossRefPubMedPubMedCentral

21.

Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H: Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J Biol Chem. 2000, 275: 33008-33013. 10.1074/jbc.M001836200.CrossRefPubMed

22.

Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening SA: Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem. 1996, 42: 2043-2045.PubMed

23.

Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9.CrossRefPubMed

24.

Hemmerlein B, Johanns U, Halbfass J, Bottcher T, Heuser M, Radzun HJ, Thelen P: The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide. Int J Oncol. 2004, 24: 1069-1076.PubMed

25.

Flisiak R, Jaroszewicz J, Lapinski TW, Flisiak I, Prokopowiczi D: Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World J Gastroenterol. 2005, 11: 6833-6838.CrossRefPubMedPubMedCentral

26.

Keyszer G, Lambiri I, Keysser M, Keysser C, Nagel R, Burmester GR, Jung K: Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. Z Rheumatol. 1998, 57: 392-398. 10.1007/s003930050131.CrossRefPubMed

27.

Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D, Loening SA: Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem. 1997, 30: 491-496. 10.1016/S0009-9120(97)00097-0.CrossRefPubMed

28.

Kramar A, Faraggi D, Fortune A, Reiser B: mROC: a computer program for combining tumour markers in predicting disease states. Comput Methods Programs Biomed. 2001, 66: 199-207. 10.1016/S0169-2607(00)00129-2.CrossRefPubMed

29.

Gordi T, Khamis H: Simple solution to a common statistical problem: interpreting multiple tests. Clin Ther. 2004, 26: 780-786. 10.1016/S0149-2918(04)90078-1.CrossRefPubMed

30.

Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993, 39: 561-577.PubMed

31.

Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993, 53: 5365-5369.PubMed

32.

Kanayama H: Matrix metalloproteinases and bladder cancer. J Med Invest. 2001, 48: 31-43.PubMed

33.

Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, Sotsiou F, Pintzas A: Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res. 2000, 20: 2009-2013.PubMed

34.

Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M: Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. 1992, 7: 77-83.PubMed

35.

Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, Stravodimos C, Giannopoulos A: Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res. 2003, 9: 5573-5581.PubMed

36.

Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD: Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer. 2006, 94: 569-577. 10.1038/sj.bjc.6602931.CrossRefPubMedPubMedCentral

37.

Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol. 1998, 160: 1914-1918. 10.1016/S0022-5347(01)62443-1.CrossRefPubMed

38.

Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001, 7: 3113-3119.PubMed

39.

Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer. 1996, 78: 2379-2387. 10.1002/(SICI)1097-0142(19961201)78:11<2379::AID-CNCR17>3.0.CO;2-Y.CrossRefPubMed

40.

Jung K, Meisser A, Bischof P: Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer. 2005, 116: 1000-1001. 10.1002/ijc.21129.CrossRefPubMed

41.

Meisser A, Cohen M, Bischof P: Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem. 2005, 51: 274-276. 10.1373/clinchem.2004.041707.CrossRefPubMed

42.

Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE: Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem. 2005, 344: 147-149. 10.1016/j.ab.2005.04.038.CrossRefPubMed

43.

Friedel R, Diederichs F, Lindena J: Release and extracellular turnover of cellular enzymes. Advances in clinical enzymology. Edited by: Schmidt E, Schmidt FW, Trautschold I and Friedel R. 1979, Basel, Karger, 70-105.

44.

Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006, 6: 227-239. 10.1038/nrc1821.CrossRefPubMed

45.

Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T: Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer. 2002, 86: 1876-1883. 10.1038/sj.bjc.6600366.CrossRefPubMedPubMedCentral

46.

Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 2006, 233: 98-107. 10.1016/j.canlet.2005.03.003.CrossRefPubMed

47.

Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H: Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem. 2006, 52: 838-844. 10.1373/clinchem.2005.064253.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/6/19/prepub

Title: Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder
Authors: Andrea Staack
Steffen Badendieck
Dietmar Schnorr
Stefan A Loening
Klaus Jung
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2006
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/1471-2490-6-19

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2006

Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia

Laparoscopic nephrectomy for giant staghorn calculus with non-functioning kidneys: Is associated unsuspected urothelial carcinoma responsible for conversion? Report of 2 cases

Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer

Testicular seminoma – unusual histology and staging with sub epithelial spread of seminoma along the vas deferans

Ectopic thyroid in an adrenal mass: a case report

Adenocarcinoma of the caecum metastatic to the bladder: an unusual cause of haematuria